Study identifier:D961WC00001
ClinicalTrials.gov identifier:NCT03553563
EudraCT identifier:2018-000213-20
CTIS identifier:N/A
An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients with Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated with Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin
reflux esophagitis
Phase 3
No
D961H capsule 10mg, D961H sachet 10mg
All
51
Interventional
1 Years - 14 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and to assess the safety and efficacy of D961H in Japanese paediatric patients treated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy who have a documented medical history of gastric ulcer or duodenal ulcer diagnosis. Doses of D961H in this study is set for the 2 groups (weight more than equal 10 kg to less than 20 kg and weight more than equal 20 kg) in the maintenance therapy for healed reflux esophagitis group and the prevention of gastric ulcer or duodenal ulcer recurrence by non-steroidal anti-inflammatory drugs or low-dose aspirin therapy group, Primary endpoints are evaluated at week 32. Further, this study is designed to evaluate the long term efficacy and safety of D961H for a maximum of 52 weeks, in consideration of the medical needs for long term proton pump inhibitor treatment. Patient can continue study treatment up to 52 weeks, if they want
Subjects are allocated to four groups based on their disease and weight. Number of Subjects Maintenance therapy for healed reflux esophagitis study part: ・Group1:aged 1 to 14 years (weight more than equal 10 kg to less than 20 kg ), Maintenance phase, n=5 to 10 ・Group2:aged 1 to 14 years (weight more than equal 20 kg), Maintenance phase, n=10 to 20 Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: ・Group3:aged 1 to 14 years (weight more than equal 10 kg to less than 20 kg), n=5 to 10 at Week 0 ・Group4:aged 1 to 14 years (weight more than equal 20 kg), n=10 to 20 at Week 0 All subjects have a D961H administration for 32 or 52 weeks. all esophagogastroduodenoscopy findings are reviewed by central evaluation committee and study is conducted based on the judgement of central evaluation committee. Data are entered in electric data capture system at study site by site staffs and all data are verified with source data by site monitors during the study. Analyses will be performed by AstraZeneca or its representatives. A comprehensive statistical analysis plan will be developed and finalised before database lock and will describe the subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints. Any deviations from this plan will be reported in the clinical study report. Efficacy analyses are intended for Efficacy Analysis Set. ・Efficacy Analysis Set:All subjects who take at least 1 dose of the investigational product and have at least 1 efficacy datum assessment during the maintenance/prevention therapy period, and who have no important protocol deviation. All safety analyses are performed on the Safety Analysis Set. ・Safety Analysis Set:All subjects who take at least 1 dose of the investigational product and have any post-treatment assessment. Frequency and incidence rate of adverse events (AEs), serious adverse events (SAEs), discontinuation of investigational product due to adverse events (DAEs) and other significant adverse events (OAEs) will be presented by MedDRA System Organ Class (SOC) and Preferred Term (PT) for each group. In addition, summaries of AEs will be further broken down by maximum intensity and relationship to the investigational product as assigned by investigators
Location
Location
Matsumoto-shi, Japan, 390-8621
Location
Fuji-shi, Japan, 417-8567
Location
Okayama-shi, Japan, 701-1192
Location
Shinjuku-ku, Japan, 160-0023
Location
Bunkyo-ku, Japan, 113-8431
Location
Maebashi-shi, Japan, 371-8511
Location
Kagoshima-shi, Japan, 890-8520
Location
Saitama-shi, Japan, 339-8551
Arms | Assigned Interventions |
---|---|
Experimental: Group1 Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily | Drug: D961H capsule 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole Drug: D961H sachet 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole |
Experimental: Group2 Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator’s discretion | Drug: D961H capsule 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole Drug: D961H sachet 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole |
Experimental: Group3 D961H 10 mg once-daily (32 or 52 weeks) | Drug: D961H capsule 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole Drug: D961H sachet 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole |
Experimental: Group4 D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator’s discretion (32 or 52 weeks) | Drug: D961H capsule 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole Drug: D961H sachet 10mg All Groups can select either capsule or sachet during the study. Other Name: esomeprazole |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.